{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:17:12Z","timestamp":1772695032100,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n                           <jats:italic toggle=\"yes\">BRAF<\/jats:italic> gene fusions have been well-described in Spitzoid melanocytic lesions but can also occur uncommonly in conventional melanomas. Here we report a series of 17 melanomas harboring <jats:italic toggle=\"yes\">BRAF<\/jats:italic> gene fusions as their putative primary genetic driver. All but one of these tumors occurred in adults (age range 13 to 96) with a relatively even sex distribution (41% female) and a broad distribution of anatomic sites. None of the tumors showed typical Spitzoid histomorphologic features. Molecular analysis identified the first example of <jats:italic toggle=\"yes\">BRAF<\/jats:italic> kinase domain duplication in melanoma, which raises interesting questions regarding the mechanism of fusion-induced BRAF activation. Although we did not identify histomorphologic features that could distinguish <jats:italic toggle=\"yes\">BRAF<\/jats:italic>-fused melanomas from more conventional melanomas, we did observe a generally low tumor mutational burden and a lower rate of UV-associated mutational signatures (3\/17; 18%), suggesting that <jats:italic toggle=\"yes\">BRAF<\/jats:italic>-fused melanomas are molecularly and mechanistically distinct from conventional cutaneous melanomas. We report detailed treatment information and clinical outcomes for this series, with most patients having shown disease progression on systemic immunotherapy (8\/12; 67%). Our results highlight the need for continued molecular subclassification to yield a comprehensive understanding of melanoma pathogenesis and have potential implications for therapeutic selection in <jats:italic toggle=\"yes\">BRAF<\/jats:italic>-fused and perhaps other unconventional forms of melanoma.<\/jats:p>","DOI":"10.1097\/pas.0000000000002370","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T08:00:19Z","timestamp":1739433619000},"page":"429-438","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["BRAF Gene Fusions in Melanoma"],"prefix":"10.1097","volume":"49","author":[{"given":"Igor","family":"Odintsov","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pissaloux","sequence":"additional","affiliation":[{"name":"INSERM 1052, CNRS 5286, Cancer Research Center of Lyon"},{"name":"Department of Biopathology, Centre Leon Bernard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Tirode","sequence":"additional","affiliation":[{"name":"Department of Biopathology, Centre Leon Bernard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"de la Fouchardiere","sequence":"additional","affiliation":[{"name":"INSERM 1052, CNRS 5286, Cancer Research Center of Lyon"},{"name":"Department of Biopathology, Centre Leon Bernard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"R1-20250416","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/PAS.0000000000000568","article-title":"Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp","volume":"40","author":"Costa","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R2-20250416","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/pcmr.12708","article-title":"Oncogenic signaling in uveal melanoma","volume":"31","author":"Park","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"R3-20250416","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/his.14735","article-title":"Melanoma arising in extracutaneous cellular blue naevus: report of two cases with comparison to cutaneous counterparts and uveal melanoma","volume":"81","author":"Jo","year":"2022","journal-title":"Histopathology"},{"key":"R4-20250416","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41467-017-00758-3","article-title":"Combined activation of MAP kinase pathway and \u03b2-catenin signaling cause deep penetrating nevi","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun"},{"key":"R5-20250416","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/cup.14393","article-title":"Deep-penetrating-nevus-like melanoma arising in patients with familial adenomatous polyposis syndrome","volume":"50","author":"Russell-Goldman","year":"2023","journal-title":"J Cutan Pathol"},{"key":"R6-20250416","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000002302","article-title":"The clinical, morphologic, and molecular spectrum of BRAF fusion spitz tumors","author":"Sharma","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"R7-20250416","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"key":"R8-20250416","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"R9-20250416","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/cancers16071347","article-title":"Targeted DNA sequencing of cutaneous melanoma identifies prognostic and predictive alterations","volume":"16","author":"Haugh","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R10-20250416","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.modpat.2023.100149","article-title":"Spectrum of melanocytic tumors harboring BRAF gene fusions: 58 cases with histomorphologic and genetic correlations","volume":"36","author":"Roy","year":"2023","journal-title":"Mod Pathol"},{"key":"R11-20250416","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","article-title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition","volume":"19","author":"Hutchinson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R12-20250416","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1159\/000533822","article-title":"Effectiveness treatment of a BRAF-ZKSCAN5 fusion gene melanoma case with dabrafenib\/trametinib","volume":"16","author":"Kato","year":"2023","journal-title":"Case Rep Oncol"},{"key":"R13-20250416","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41379-022-01138-z","article-title":"Identification of fusions with potential clinical significance in melanoma","volume":"35","author":"Moran","year":"2022","journal-title":"Mod Pathol"},{"key":"R14-20250416","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41379-019-0445-z","article-title":"Spitz melanoma is a distinct subset of spitzoid melanoma","volume":"33","author":"Raghavan","year":"2020","journal-title":"Mod Pathol"},{"key":"R15-20250416","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/pcmr.12148","article-title":"Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy","volume":"26","author":"Botton","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"R17-20250416","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"R19-20250416","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/gcc.23026","article-title":"Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosis","volume":"61","author":"Macagno","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"R20-20250416","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamaoncol.2015.4437","article-title":"Identification of BRAF kinase domain duplications across multiple tumor types and response to RAF inhibitor therapy","volume":"2","author":"Klempner","year":"2016","journal-title":"JAMA Oncol"},{"key":"R21-20250416","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.str.2021.02.005","article-title":"B-Raf autoinhibition in the presence and absence of 14-3-3","volume":"29","author":"Zhang","year":"2021","journal-title":"Structure"},{"key":"R22-20250416","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41467-021-21613-6","article-title":"Structure\u2013function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting","volume":"12","author":"Du","year":"2021","journal-title":"Nat Commun"},{"key":"R23-20250416","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses","volume":"29","author":"Botton","year":"2019","journal-title":"Cell Rep"},{"key":"R24-20250416","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00432-022-03939-w","article-title":"TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy","volume":"149","author":"Eckardt","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R25-20250416","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1172\/JCI33656","article-title":"BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas","volume":"118","author":"Pfister","year":"2008","journal-title":"J Clin Investig"},{"key":"R26-20250416","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Yao","year":"2019","journal-title":"Nat Med"},{"key":"R27-20250416","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/acs.jmedchem.3c01830","article-title":"The discovery of exarafenib (KIN-2787): overcoming the challenges of Pan-RAF kinase inhibition","volume":"67","author":"Chen","year":"2024","journal-title":"J Med Chem"},{"key":"R28-20250416","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/onc.2016.486","article-title":"Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK\/PI3K inhibition or MEK\/CDK4\/6 inhibition","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"R29-20250416","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-20-4189","article-title":"Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas","volume":"27","author":"Shoushtari","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R30-20250416","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1158\/1078-0432.CCR-17-0070","article-title":"Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4\/6 inhibitors in targeted therapy","volume":"23","author":"Kong","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:00:35Z","timestamp":1744812035000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002370"}},"subtitle":["First Kinase Domain Duplication, New Fusion Partners, and Clinical Outcomes"],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002370","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}